Fortress Financial Statements From 2010 to 2026

FBIO Stock  USD 3.40  0.08  2.30%   
Fortress Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Fortress Biotech's valuation are provided below:
Gross Profit
19.9 M
Profit Margin
0.064
Market Capitalization
105.5 M
Enterprise Value Revenue
1.4061
Revenue
62.3 M
We have found one hundred twenty available fundamental signals for Fortress Biotech, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Fortress Biotech's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 25th of January 2026, Market Cap is likely to grow to about 91.9 M, while Enterprise Value is likely to drop about 34.3 M.

Fortress Biotech Total Revenue

47.2 Million

Check Fortress Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fortress Biotech's main balance sheet or income statement drivers, such as Interest Expense of 7 M, Other Operating Expenses of 124.4 M or Research Development of 56.6 M, as well as many indicators such as Price To Sales Ratio of 0.8, Dividend Yield of 0.0776 or PTB Ratio of 2.03. Fortress financial statements analysis is a perfect complement when working with Fortress Biotech Valuation or Volatility modules.
  
Build AI portfolio with Fortress Stock
Check out the analysis of Fortress Biotech Correlation against competitors.
To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.

Fortress Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding25.1 M23.9 M7.2 M
Slightly volatile
Total Assets172.5 M165.9 M166.6 M
Slightly volatile
Short and Long Term Debt Total59.3 M87.4 M56.2 M
Slightly volatile
Other Current Liabilities26.1 M40.9 M26.2 M
Slightly volatile
Total Current Liabilities49 M82.1 M49.6 M
Slightly volatile
Property Plant And Equipment Net14.9 M19.7 M14 M
Slightly volatile
Accounts Payable38.2 M36.4 M18.5 M
Slightly volatile
Cash109.1 M65.9 M102.8 M
Slightly volatile
Non Current Assets Total40.2 M61.9 M38.3 M
Slightly volatile
Non Currrent Assets Other2.8 MM7.1 M
Very volatile
Long Term Debt43.8 M66.7 M41.7 M
Slightly volatile
Cash And Short Term Investments113.1 M65.9 M106.4 M
Slightly volatile
Liabilities And Stockholders Equity172.5 M165.9 M166.6 M
Slightly volatile
Non Current Liabilities Total54.8 M85.6 M52.2 M
Slightly volatile
Other Current Assets8.7 M9.5 M8.5 M
Slightly volatile
Other Stockholder Equity922 M878.1 M443.9 M
Slightly volatile
Total Liabilities100.4 M167.7 M101.6 M
Slightly volatile
Total Current Assets134.8 M103.9 M128.5 M
Slightly volatile
Common Stock30.6 K32.2 K146.1 K
Very volatile
Common Stock Total Equity226.3 K116.2 K172.2 K
Pretty Stable
Other Liabilities2.7 M2.3 M2.3 M
Pretty Stable
Net Tangible Assets58.3 M110.5 M60.7 M
Slightly volatile
Net Receivables13.2 M12 M10 M
Slightly volatile
Capital Surpluse386.6 M754.4 M402.1 M
Slightly volatile
Property Plant And Equipment Gross17.4 M33.6 M15.1 M
Slightly volatile
Short Term Debt3.5 M3.7 MM
Slightly volatile
Current Deferred Revenue720.8 K758.7 K3.2 M
Pretty Stable
Long Term Debt Total99.5 M94.8 M52.4 M
Slightly volatile
Non Current Liabilities Other1.9 M1.6 M2.2 M
Very volatile
Short and Long Term Debt682.8 K718.8 KM
Pretty Stable
Net Invested Capital95.4 M73.2 M115.1 M
Slightly volatile
Net Working Capital16.2 M17.1 M102.3 M
Slightly volatile
Capital Stock26.5 K27.9 K438.6 K
Slightly volatile
Capital Lease Obligations18.1 M15.6 M23.5 M
Slightly volatile

Fortress Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest ExpenseM11.4 M7.3 M
Slightly volatile
Other Operating Expenses124.4 M193.3 M131 M
Slightly volatile
Research Development56.6 M65.4 M58 M
Slightly volatile
Total Operating Expenses102.9 M169.3 M108.9 M
Slightly volatile
Selling General Administrative105.9 M100.9 M54.6 M
Slightly volatile
Depreciation And Amortization3.1 M5.1 MM
Slightly volatile
Non Recurring20.5 M18 M16.1 M
Slightly volatile
Interest Income1.9 M3.1 M2.3 M
Slightly volatile
Selling And Marketing Expenses187.4 M178.5 M95.3 M
Slightly volatile
Tax Provision463.2 K280.8 K887.1 K
Slightly volatile
Reconciled Depreciation6.2 M5.1 M4.7 M
Slightly volatile

Fortress Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow113.3 M67.6 M106.7 M
Slightly volatile
Stock Based Compensation39.4 M37.5 M15.9 M
Slightly volatile
Begin Period Cash Flow116.2 M95.9 M105.7 M
Slightly volatile
Depreciation3.2 M5.1 MM
Slightly volatile
Issuance Of Capital Stock88.7 M74.6 M73.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.80.8446.0832
Slightly volatile
Dividend Yield0.07760.10.0568
Slightly volatile
Days Sales Outstanding84.959.25105
Pretty Stable
Stock Based Compensation To Revenue0.620.656.118
Slightly volatile
Capex To Depreciation3.673.8667.932
Slightly volatile
Inventory Turnover1.581.6681.066
Pretty Stable
Days Of Inventory On Hand23822777.1694
Slightly volatile
Payables Turnover0.720.761.5804
Very volatile
Sales General And Administrative To Revenue1.661.759.8142
Slightly volatile
Research And Ddevelopement To Revenue1.081.1313.2146
Slightly volatile
Capex To Revenue0.280.35.0553
Slightly volatile
Cash Per Share2.362.4827.102
Pretty Stable
Days Payables Outstanding6046361.6 K
Slightly volatile
Income Quality0.580.60.7216
Very volatile
Intangibles To Total Assets0.210.20.0809
Slightly volatile
Current Ratio1.381.464.4801
Slightly volatile
Receivables Turnover5.066.384.2318
Pretty Stable
Capex Per Share1.270.651.7845
Very volatile
Revenue Per Share3.033.198.7864
Pretty Stable
Interest Debt Per Share3.533.7213.5236
Pretty Stable
Debt To Assets0.250.470.3159
Slightly volatile
Operating Cycle157286173
Slightly volatile
Days Of Payables Outstanding6046361.6 K
Slightly volatile
Ebt Per Ebit1.181.261.0663
Pretty Stable
Quick Ratio1.161.224.418
Slightly volatile
Net Income Per E B T0.590.440.6435
Slightly volatile
Cash Ratio0.880.923.8106
Slightly volatile
Days Of Inventory Outstanding23822777.1694
Slightly volatile
Days Of Sales Outstanding84.959.25105
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.241.371.1845
Very volatile
Fixed Asset Turnover4.483.873.7096
Very volatile
Debt Ratio0.250.470.3159
Slightly volatile
Price Sales Ratio0.80.8446.0832
Slightly volatile
Asset Turnover0.220.360.1945
Slightly volatile
Gross Profit Margin0.460.570.4711
Slightly volatile

Fortress Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap91.9 M48.5 M64.2 M
Slightly volatile

Fortress Fundamental Market Drivers

Forward Price Earnings344.8276
Cash And Short Term Investments57.3 M

Fortress Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fortress Biotech Financial Statements

Fortress Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Fortress Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue758.7 K720.8 K
Total Revenue66.3 M47.2 M
Cost Of Revenue24 M28.4 M
Stock Based Compensation To Revenue 0.65  0.62 
Sales General And Administrative To Revenue 1.75  1.66 
Research And Ddevelopement To Revenue 1.13  1.08 
Capex To Revenue 0.30  0.28 
Revenue Per Share 3.19  3.03 
Ebit Per Revenue(1.72)(1.81)

Pair Trading with Fortress Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Fortress Stock

  0.63DSGN Design TherapeuticsPairCorr

Moving against Fortress Stock

  0.84AAPG Ascentage Pharma Symbol ChangePairCorr
  0.81LEGN Legend Biotech CorpPairCorr
  0.75CCCC C4 TherapeuticsPairCorr
  0.74GALT Galectin TherapeuticsPairCorr
  0.7RARE UltragenyxPairCorr
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Fortress Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fortress Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fortress Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fortress Biotech Stock:
Check out the analysis of Fortress Biotech Correlation against competitors.
To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.12)
Revenue Per Share
2.324
Quarterly Revenue Growth
0.205
Return On Assets
(0.34)
Return On Equity
(2.05)
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.